Showing 5781-5790 of 8544 results for "".
- Study Shows Teledermatology Gaining Traction, While Challenges Remainhttps://practicaldermatology.com/news/study-shows-teledermatology-gaining-traction-with-challenges/2471061/Newly published research explored patient perceptions and satisfaction with teledermatology services in the post-pandemic era, showing high satisfaction rates and preferences for hybrid care models. The study surveyed a diverse group of dermatology patients who had utilized teledermatology
- Baricitinib Enhances Phototherapy Efficacy in Adults with Active Vitiligohttps://practicaldermatology.com/news/baricitinib-enhances-phototherapy-efficacy-in-severe-atopic-dermatitis/2471046/Baricitinib combined with narrowband UV-B achieved a modest reduction in disease severity in adults with severe, active nonsegmental vitiligo, but did not meet the prespecified threshold for sufficient repigmentation, new research revealed. The trial enrolled 49 adul
- Analysis: Age and Sex Shape Pyogenic Granuloma Patternshttps://practicaldermatology.com/news/analysis-age-and-sex-shape-pyogenic-granuloma-patterns/2471030/An analysis of more than 1,000 pathologically confirmed pyogenic granulomas (PGs) showed distinct age and sex patterns in their distribution, challenging previous understanding of their etiology. Researchers for the analysis examined 1,009 PG cases reported between 2010 and 2020 at a tert
- Study: Safety Signals Emerge for IL-23 and IL-12/23 Inhibitors in Psoriasis Treatmenthttps://practicaldermatology.com/news/safety-signals-emerge-for-il-23-and-il-1223-inhibitors-in-psoriasis-treatment/2470971/A new analysis of psoriasis patients indicates an emergence of new safety signals associated with interleukin-23 (IL-23) inhibitors and the IL-12/23 inhibitor ustekinumab. Researchers on the study analyzed 41.4 million adverse event (AE) reports from the FDA Adverse Event Reporting System
- Analysis: FDA Approvals Highlight Disparities in Oncology Outcomes by Ancestryhttps://practicaldermatology.com/news/analysis-fda-approvals-highlight-disparities-oncology-outcomes-ancestry/2470889/Patients of African ancestry remain underrepresented in eligibility for biomarker-driven precision oncology therapies, according to a new study in JAMA Dermatology. The retrospective analysis of 59,433 patients with solid cancers looked at genetic sequencing data from MSK-IMPACT a
- Illuminate PRP Adds Industry Veteran Redmond as CCOhttps://practicaldermatology.com/news/illuminate-prp-adds-industry-veteran-redmond-cco/2470885/Industry veteran Jennifer Redmond, MBA, joined Illuminate PRP as Chief Commercial Officer, the company announced. “Jennifer brings a wealth of experience in sales and marketing within the aesthetics and pharmaceutical industries, along with strong leadership and a commitment to driving pos
- PPIs, H2RAs Can Increase Psoriasis Risk for Patients With GI Diseaseshttps://practicaldermatology.com/news/ppis-h2ras-can-increase-psoriasis-risk-patients-gi-diseases/2470871/Prolonged use of proton pump inhibitor (PPI) or histamine-2 receptor antagonists (H2RA) is associated with the risk of psoriasis among patients with gastrointestinal diseases, according to a new study published in the Korean Journal of Internal Medicine. The study included 3,662 p
- Skin Cancer Foundation Names New Executive Directorhttps://practicaldermatology.com/news/skin-cancer-foundation-names-new-executive-director/2470856/The Skin Cancer Foundation (SCF), a national nonprofit organization that is committed to decreasing the incidence and mortality of the world’s most common cancer through public education, announced that it has appointed Becky Kamowitz to the role of executive director. Kamowitz has worked
- VYNE Therapeutics Completes Enrollment for Phase 2b Trial of VYN201 in Nonsegmental Vitiligohttps://practicaldermatology.com/news/vyne-therapeutics-completes-enrollment-phase-2b-trial-vyn201-nonsegmental-vitiligo/2470854/VYNE Therapeutics Inc. has finalized enrollment for its Phase 2b trial of VYN201, a once-daily topical gel for nonsegmental vitiligo, with initial data from the 24-week double-blind portion anticipated in mid-2025, according to a news release from the manufacturer. The randomized, double-b
- Genetic Study Reveals Psoriasis-Sudden Hearing Loss Connectionhttps://practicaldermatology.com/news/genetic-study-reveals-psoriasis-hearing-loss-connection/2470853/A recent genetic study has established a causal relationship between psoriasis and an elevated risk of sudden sensorineural hearing loss (SSNHL). Researchers derived the findings using Mendelian randomization (MR) analysis to identify potential connections between inflammatory skin disease